Ex Parte YanantonDownload PDFBoard of Patent Appeals and InterferencesJan 12, 201211169738 (B.P.A.I. Jan. 12, 2012) Copy Citation UNITED STATES PATENT AND TRADEMARK OFFICE UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 11/169,738 06/30/2005 Patrick Yananton 1747 4053 33055 7590 01/13/2012 PATENT, COPYRIGHT & TRADEMARK LAW GROUP 4199 Kinross Lakes Parkway Suite 275 RICHFIELD, OH 44286 EXAMINER ANDERSON, CATHARINE L ART UNIT PAPER NUMBER 3764 MAIL DATE DELIVERY MODE 01/13/2012 PAPER Please find below and/or attached an Office communication concerning this application or proceeding. The time period for reply, if any, is set in the attached communication. PTOL-90A (Rev. 04/07) UNITED STATES PATENT AND TRADEMARK OFFICE ____________________ BEFORE THE BOARD OF PATENT APPEALS AND INTERFERENCES ____________________ Ex parte PATRICK YANANTON ____________________ Appeal 2010-005027 Application 11/169,738 Technology Center 3700 ____________________ Before: CHARLES N. GREENHUT, MICHAEL C. ASTORINO, and JAMES P. CALVE, Administrative Patent Judges. GREENHUT, Administrative Patent Judge. DECISION ON REQUEST FOR REHEARING STATEMENT OF CASE This is a response to a Request for Rehearing. Requests for Rehearing are limited to matters overlooked or misapprehended by the Panel in rendering the original decision. See 37 C.F.R. § 41.52. Appeal 2010-005027 Application 11/169,738 2 OPINION The sole issue raised by Appellant is whether, by virtue of paragraph [0029] of Appellant’s Specification, Appellant defined the term “adhesion enhancing agent” to mean a substance that remains chemically inert with regard to the applied active ingredient. Request 2-3. In the litigation context, our reviewing court has debated the issue of construing a claim such that the “metes and bounds of what the inventor claims extend beyond what he has invented or disclosed in the specification.” See Retractable Techs., Inc. v. Becton, Dickinson & Co., 659 F.3d 1369, 1369-73 (Fed. Cir. Oct. 31, 2011) (Moore, dissenting). However, during examination, where an applicant has the ability to amend his claims, the PTO is obligated to give claims their broadest reasonable interpretation consistent with the specification, and to read claim language in light of the specification as it would be interpreted by one of ordinary skill in the art. In re Am. Acad. of Sci. Tech Ctr., 367 F.3d 1359, 1364 (Fed. Cir. 2004) (citations omitted). While the specification should be used to interpret the meaning of a claim, it is improper to confine the claims to the embodiments found in the specification. In re Trans Texas Holdings Corp., 498 F.3d 1290, 1299 (Fed. Cir. 2007) (citations omitted). In addition to the specification, dictionary definitions are also pertinent in this analysis. Id. “An inventor is free to define the specific terms used to describe his or her invention, [but] this must be done with reasonable clarity, deliberateness, and precision.” In re Paulsen, 30 F.3d 1475, 1480 (Fed. Cir. 1994). Paragraph [0029] of Appellant’s Specification states that the term “adhesion enhancing agent” is synonymous with the term “cling agent.” In relevant part, paragraph [0029] makes two statements regarding the “cling agent.” First, “the term ‘cling agent’ refers to any ingredient or compositions Appeal 2010-005027 Application 11/169,738 3 of ingredients that can be used to dip, tumble, spray or otherwise coat individual fibers, crossovers and cellular structures of any fibers, nonwoven, etc. pad.” Id. Second, “[t]he critical feature to any of the cling agents or adhering substance is that they remain chemically inert with regard to the applied active ingredient.” Id. The first statement is clearly a lexicographic definition—a very broad one. The second statement describes a “critical feature” of any of the cling agents or adhering substances. While the second statement more narrowly limits cling agents to a particular type, i.e., a preferred embodiment – those that remain chemically inert with regard to the applied active ingredient – it would not be regarded by one of ordinary skill in the art as altering the meaning of the term “cling agent” itself. This is particularly true in light of the fact that Appellant presents one and only one clear, deliberate and precise definition of the term – “any ingredient or compositions of ingredients that can be used to dip, tumble, spray or otherwise coat individual fibers, crossovers and cellular structures of any fibers, nonwoven, etc. pad.” This statement demonstrates Appellant’s intent for the term “cling agent,” and therefore the synonymous “adhesion enhancing agent,” to include any ingredient or compositions of ingredients that can coat substrate fibers in a variety of ways. Thus, it is this broad definition that controls our interpretation of the term. This broad definition contains no language confining the meaning of “adhesion enhancing agent” to an agent that enhances adhesion specifically by a mechanism other than a chemical bond. Opinion 5. Appellant chose to use language in the claims that is broader than the language used to describe the preferred embodiments and we will not import language used to describe the preferred embodiments into the claims. Accordingly, we do not agree with Appellant that, when read in light of the Appeal 2010-005027 Application 11/169,738 4 Specification, one of ordinary skill in the art would understand “adhesion enhancing agent” to mean a substance that remains chemically inert with regard to the applied active ingredient. For the forgoing reasons, Appellant failed to convince us that any matter has been misapprehended or overlooked in rendering of our original Decision. Reconsideration has been Granted to the extent that we reconsidered our previous decision. It is Denied with respect to making any changes thereto. DECISION Upon reconsideration, the rejections of claims 1, 2, 4-7, 11, 12, and 15-19 remain affirmed. RECONSIDERATION DENIED nlk Copy with citationCopy as parenthetical citation